A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients

Phase II Study of Pegylated Arginine Deiminase for Nonresectable and Metastatic Hepatocellular Carcinoma

(2010) Evan S. Glazer et al.   JOURNAL OF CLINICAL ONCOLOGY

ADI, autophagy and apoptosis: Metabolic stress as a therapeutic option for prostate cancer

(2009) Randie H. Kim et al.   Autophagy

Alpha-Fetoprotein Response in Advanced Hepatocellular Carcinoma Receiving Cytostatic Agent

(2009) Li-Tzong Chen et al.   JOURNAL OF CLINICAL ONCOLOGY

Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase

(2008) Tawnya L. Bowles et al.   INTERNATIONAL JOURNAL OF CANCER

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE

The impact of new data in the treatment of advanced hepatocellular carcinoma

(2008) Ghassan K. Abou-Alfa et al.   Current Oncology Reports

Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma

(2007) Andrew X. Zhu   CANCER

Role of arginine metabolism in immunity and immunopathology

(2007) Elisa Peranzoni et al.   IMMUNOBIOLOGY